The ischemic type of central retinal vein occlusion (CRVO) is associated with a poor visual and ocular prognosis. Although several reports have indicated that hemodilution or thrombolytic therapy may be of benefit, there is still no consensus among ophthalmologists about the management of this disorder. In our study, we retrospectively evaluated the visual outcome after medical treatment in 58 patients with ischemic CRVO and severe visual loss (≤20/50). We separately investigated three different groups, depending on the following criteria: onset of symptoms within 11 days prior to admission and thrombolytic treatment with 50 mg of recombinant tissue plasminogen activator (rtPA) and intravenous heparinization (n = 23) or hemodilution therapy (n = 22) or onset of symptoms >11 days before the initial visit and hemodilution (n = 13). An advancement of 2 or more lines on the logarithmic visual acuity chart was noted in 10 cases (44%) in the rtPA group and in 3 subjects (14%) in the early-phase hemodilution group, whereas only 1 patient in the late-phase hemodilution group showed a comparable improvement. Our findings suggest that treatment with low-dose rtPA or hemodilution aimed at early restoration of blood flow has the potential to improve the visual prognosis in ischemic CRVO. The finding that thrombolysis had a favorable outcome supports the hypothesis that specific subgroups of patients may benefit from this therapeutic approach. Further investigation will be required to definitively prove the effectiveness of fibrinolytic agents.

Keywords:
Ischemic central retinal vein occlusion, Frontloading thrombolytic therapy, Recombinant tissue plasminogen activator, Hemodilution
1.
Quinlan PM, Elman MJ, Bhatt AK, Mardesich P, Enger C: The natural course of central retinal vein occlusion. Am J Ophthalmol 1990;110:118–123.
2.
Hayreh SS, Rojas P, Podhajsky P, Montague P, Woolson RF: Ocular neovascularization with retinal vascular occlusion. III. Incidence of ocular neovascularization with retinal vein occlusion. Ophthalmology 1983;90:488–506.
3.
Zegarra H, Gutman FA, Conforto J: The natural course of central retinal vein occlusion. Ophthalmology 1979;86:1931–1942.
4.
Central Vein Occlusion Study Group N Report: A randomized clinical trial of early panretinal photocoagulation for ischemic central vein occlusion. Ophthalmology 1995;102:1434–1444.
5.
Chen HC, Wiek J, Gupta A, Luckie A, Kohner EM: Effect of isovolaemic haemodilution on visual outcome in branch retinal vein occlusion. Br J Ophthalmol 1998;82:162–167.
6.
Hansen LL, Wiek J, Wiederholt M: A randomised prospective study of treatment of non-ischaemic central retinal vein occlusion by isovolaemic haemodilution. Br J Ophthalmol 1989;73:895–899.
7.
Wolf S, Arend B, Bertram B, Schulte K, Kaufhold F, Teping C, Reim M: Hämodilution bei Patienten mit Zentralvenenthrombose der Retina. Fortschr Ophthalmol 1991;88:35–43.
8.
Wolf S, Arend O, Bertram B, Remky A, Schulte K, Wald KJ, Reim M: Hemodilution therapy in central retinal vein occlusion: One-year results of a prospective randomized study. Graefes Arch Clin Exp Ophthalmol 1994;232:33–39.
9.
Glacet-Bernard A, Coscas G, Chabanel A, Zourdani A, Lelong F, Samama MM: A randomised, double masked study on the treatment of retinal vein occlusion with troxerutin. Am J Ophthalmol 1994;118:421–429.
10.
Green WR, Chan CC, Hutchins GM, Terry JM: Central retinal vein occlusion. A prospective histopathologic study of 29 eyes in 28 cases. Retina 1981;1:27–55.
11.
Smith P, Green WR, Miller NR, Terry JM: Clinicopathologic case report of bilateral central retinal vein occlusion in Reye’s syndrome. Arch Ophthalmol 1980;98:1256–1260.
12.
Chesebro JH, Knatterud G, Roberts R: Thrombolysis in myocardial infarction (TIMI) trial, phase I: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase: Clinical findings through hospital discharge. Circulation 1987;76:142–154.
13.
ISIS-3 (Third International Study of Infarct Survival) Collaborative Group: ISIS-3: A randomised comparison of streptokinase versus tissue plasminogen activator versus anistreplase and of aspirin plus heparin versus aspirin alone among 41,299 cases of suspected myocardial infarction. Lancet 1993;339:753–770.
14.
The GUSTO Investigators: An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993;329:673–682.
15.
The GUSTO angiographic investigators: The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. N Engl J Med 1993;329:1615–1622.
16.
Verstraete M, Bernard R, Bory M: Randomised trial of intravenous recombinant tissue-type plasminogen activator versus intravenous streptokinase in acute myocardial infarction: Report from the European Cooperative Study Group for Recombinant Tissue-Type Plasminogen Activator. Lancet 1985;i:842–847.
17.
Goldhaber SZ: Alteplase versus heparin in acute pulmonary embolsim: Randomised trial assessing right-ventricular function and pulmonary perfusion. Lancet 1993;341:507–511.
18.
Goldhaber SZ, Meyerovitz MF, Green D: Randomized controlled trial of tissue plasminogen activator in proximal deep venous thrombosis. Am J Med 1990;88:235–240.
19.
The National Institute of Neurological Disorders and Stroke rt-PA Study Group: Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995;333:1581–1587.
20.
The Thrombolysis or Peripheral Arterial Surgery (TOPAS) Investigators: A comparison of recombinant urokinase with vascular surgery as initial treatment for acute arterial occlusion of the legs. N Engl J Med 1998;338:1105–1111.
21.
Hattenbach LO: Systemische Lysetherapie bei retinalen Gefässverschlüssen. Ophthalmologe 1998;95:568–575.
22.
Hattenbach LO, Steinkamp GWK, Scharrer I, Ohrloff C: Fibrinolytic therapy with low-dose recombinant tissue plasminogen activator in retinal vein occlusion. Ophthalmologica 1998;212:394–398.
23.
Kohner EM, Pettit JE, Hamilton AM: Streptokinase in central retinal vein occlusion: A controlled clinical trial. Br Med J 1976;1:550–553.
24.
Kreutzer A, Brunner R, Schäfer H-J, Sickel W, Auel H, Hossmann V: Lysetherapie mit rt-PA bei Patienten mit Stamm- oder Zentralvenenocclusion der Retina. Fortschr Ophthalmol 1988;85:511–513.
25.
Metzler de Höhmann U: Fibrinolyse und Antikoagulantientherapie bei retinalen Venenverschlüssen. Marburg a.d. Lahn, Medizinische Verlagsgesellschaft mbH, 1977.
26.
Brott TG, Haley EC Jr, Levy DE: Urgent therapy for stroke. I. Pilot study of tissue plasminogen activator administered within 90 minutes. Stroke 1992;23:632–640.
27.
Haley EC Jr, Levy DE, Brott TG: Urgent therapy for stroke. II. Pilot study of tissue plasminogen activator administered 91–180 minutes from onset. Stroke 1992;23:641–645.
28.
Hattenbach LO, Klais C, Scharrer I: Heparin cofactor II deficiency in central retinal vein occlusion. Acta Ophthalmol Scand 1998;76:758–759.
29.
Glacet-Bernard A, Coscas G, Chabanel A, Zourdani A, Lelong F, Samama MM: Prognostic factors for retinal vein occlusion. Ophthalmology 1996;103:551–560.
30.
Reim M, Bertram B, Wolf S: Behandlungsversuche der Zentralvenenthrombose der Netzhaut mit Plasminogen-Aktivator (rt-PA). Klin Wochenschr 1988;66:143–149.
31.
Larsson J, Carlson J, Olsson SB: Ultrasound enhanced thrombolysis in experimental retinal vein occlusion in the rabbit. Br J Ophthalmol 1998;82:1438–1440.
32.
Oncel M, Peyman GA, Khoobehi B: Tissue plasminogen activator in the treatment of experimental retinal vein occlusion. Retina 1989;9:1–7.
33.
Dhote R, Bachmeyer C, Horellou MH, Toulon P, Christoforov B: Central retinal vein thrombosis associated with resistance to activated protein C. Am J Ophthalmol 1995;120:388–389.
34.
Galetta SL, Plock GL, Kushner MJ, Wyszynski RE, Bruckner AJ: Ocular thrombosis associated with antiphospholipid antibodies. Ann Ophthalmol 1991;23:207–212.
35.
Larsson J, Olafsdottir E, Bauer B: Activated protein C resistance in young adults with central retinal vein occlusion. Br J Ophthalmol 1996;80:200–202.
36.
Neely KA, Ernest JT, Goldstick TK, Linsenmeier RA, Moss J: Isovolemic hemodilution increases retinal tissue oxygen tension. Graefes Arch Clin Exp Ophthalmol 1996;234:688–694.
37.
Anderson JL, Karagounis L, Allan A, Bradford MJ, Menlove RL, Pryor TA: Older age and elevated blood pressure are risk factors for intracerebral hemorrhage after thrombolysis. Am J Cardiol 1991;68:166–170.
38.
Chaitman BR, Thompson B, Wittry MD, Stump D, Hamilton WP, Hillis LD, Dwyer JG, Solomon RE, Knatterud GL for the TIMI Investigators: The use of tissue plasminogen activator for acute myocardial infarction in the elderly: Results from the Thrombolysis in Myocardial Infarction Phase I Open-Label Studies, and the Thrombolysis in Myocardial Infarction Phase II Pilot Study. J Am Coll Cardiol 1989;14:1159–1165.
39.
Gore JM, Sloan M, Price TR, Randall AMY, Bovill E, Collen D, Forman S, Knatterud GL, Sopko G, Terrin ML, and the TIMI Investigators: Intracerebral hemorrhage, cerebral infarction, and subdural hematoma after acute myocardial infarction and thrombolytic therapy in the thrombolysis in myocardial infarction study: Thrombolysis in Myocardial Infarction; Phase II, Pilot and Clinical Trial. Circulation 1991;83:448–459.
40.
Sloan M, Gore JM: Ischemic stroke and intracranial hemorrhage following thrombolytic therapy for acute myocardial infarction: A risk-benefit analysis. Am J Cardiol 1992;69:21A–38A.
© 1999 S. Karger AG, Basel
1999
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.